JPWO2022120378A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022120378A5 JPWO2022120378A5 JP2023533877A JP2023533877A JPWO2022120378A5 JP WO2022120378 A5 JPWO2022120378 A5 JP WO2022120378A5 JP 2023533877 A JP2023533877 A JP 2023533877A JP 2023533877 A JP2023533877 A JP 2023533877A JP WO2022120378 A5 JPWO2022120378 A5 JP WO2022120378A5
- Authority
- JP
- Japan
- Prior art keywords
- amyloid
- organ
- reactive agent
- heart
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000056 organ Anatomy 0.000 claims 51
- 239000003795 chemical substances by application Substances 0.000 claims 42
- 210000002216 heart Anatomy 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 102100029290 Transthyretin Human genes 0.000 claims 20
- 206010002022 amyloidosis Diseases 0.000 claims 20
- 210000000952 spleen Anatomy 0.000 claims 19
- 210000003734 kidney Anatomy 0.000 claims 16
- 210000004185 liver Anatomy 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 238000001514 detection method Methods 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108010071690 Prealbumin Proteins 0.000 claims 6
- 102000009190 Transthyretin Human genes 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- VVECGOCJFKTUAX-UHFFFAOYSA-N 2-[3-fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=C(F)C(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 VVECGOCJFKTUAX-UHFFFAOYSA-N 0.000 claims 2
- NCWZOASIUQVOFA-NSCUHMNNSA-N 4-[(e)-2-[4-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]phenyl]ethenyl]-n-methylaniline Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCCF)C=C1 NCWZOASIUQVOFA-NSCUHMNNSA-N 0.000 claims 2
- 208000023761 AL amyloidosis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 claims 2
- 229940113298 flutemetamol Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011277 treatment modality Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121779P | 2020-12-04 | 2020-12-04 | |
| US63/121,779 | 2020-12-04 | ||
| PCT/US2021/072729 WO2022120378A1 (en) | 2020-12-04 | 2021-12-03 | Method for diagnosing amyloid diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553877A JP2023553877A (ja) | 2023-12-26 |
| JP2023553877A5 JP2023553877A5 (https=) | 2024-12-10 |
| JPWO2022120378A5 true JPWO2022120378A5 (https=) | 2024-12-10 |
Family
ID=79170797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533877A Pending JP2023553877A (ja) | 2020-12-04 | 2021-12-03 | アミロイド疾患を診断する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240003912A1 (https=) |
| EP (1) | EP4255508A1 (https=) |
| JP (1) | JP2023553877A (https=) |
| KR (1) | KR20230144525A (https=) |
| CN (1) | CN117460543A (https=) |
| AU (1) | AU2021393591A1 (https=) |
| CA (1) | CA3200167A1 (https=) |
| IL (1) | IL302834A (https=) |
| MX (1) | MX2023006568A (https=) |
| WO (1) | WO2022120378A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025212955A1 (en) * | 2024-04-05 | 2025-10-09 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4900540A (en) | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
| EP0231091B1 (en) | 1986-01-24 | 1993-03-31 | Children's Hospital Medical Center | Stable emulsions of highly fluorinated organic compound |
| MX9205298A (es) | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| US10213506B2 (en) * | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| EP4058479A4 (en) * | 2019-11-15 | 2024-02-28 | University of Tennessee Research Foundation | MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS |
| AU2021208630A1 (en) * | 2020-01-17 | 2022-07-21 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
-
2021
- 2021-12-03 WO PCT/US2021/072729 patent/WO2022120378A1/en not_active Ceased
- 2021-12-03 US US18/039,949 patent/US20240003912A1/en active Pending
- 2021-12-03 CA CA3200167A patent/CA3200167A1/en active Pending
- 2021-12-03 EP EP21835563.4A patent/EP4255508A1/en active Pending
- 2021-12-03 AU AU2021393591A patent/AU2021393591A1/en active Pending
- 2021-12-03 JP JP2023533877A patent/JP2023553877A/ja active Pending
- 2021-12-03 IL IL302834A patent/IL302834A/en unknown
- 2021-12-03 CN CN202180079752.XA patent/CN117460543A/zh active Pending
- 2021-12-03 MX MX2023006568A patent/MX2023006568A/es unknown
- 2021-12-03 KR KR1020237022487A patent/KR20230144525A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sasaki et al. | Clinical usefulness of scintigraphy with 99mTc-galactosyl-human serum albumin for prognosis of cirrhosis of the liver | |
| Zhu et al. | A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE | |
| JP5849117B2 (ja) | 膵島イメージング用分子プローブ前駆体及びその使用 | |
| Pruthi et al. | Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India | |
| Jazmati et al. | Exercise thallium-201 imaging in complete left bundle branch block and the prevalence of septal perfusion defects | |
| Spier et al. | FDG-PET in inflammatory bowel disease | |
| Fowler et al. | New directions in positron emission tomography-Part II | |
| Johnson et al. | The role of antimyosin antibodies in acute myocardial infarction | |
| Rajput et al. | The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease | |
| Termanini et al. | Distinguishing small hepatic hemangiomas from vascular liver metastases in gastrinoma: use of a somatostatin-receptor scintigraphic agent. | |
| Minamimoto et al. | Re-evaluating the potentials and limitations of 99mTc-aprotinin scintigraphy for amyloid imaging | |
| JPWO2022120378A5 (https=) | ||
| US20090274622A1 (en) | Necrosis avid tracer agent | |
| Yen et al. | The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related β2-microglobulin amyloid | |
| Mallin et al. | Imaging modalities in the follow-up of non-lodine avid thyroid carcinoma | |
| Ferraris et al. | Measurement of bile acid half-life using [75Se] HCAT in health and intestinal diseases: Comparison with [75Se] HCAT abdominal retention methods | |
| Schaling et al. | Possibilities and limitations of radioimmunoscintigraphy and conventional diagnostic modalities in choroidal melanoma. | |
| Tjen | Cholescintigraphy | |
| Shiomi et al. | Measurement of Portal Systemic Shunting by Oral and Per-rectal Administration of [123 I] Iodoamphetamine, and Clinical Use of the Results. | |
| Bhambhvani et al. | Nuclear imaging of cardiac amyloidosis.‘We’ve only just begun’ | |
| RH et al. | Detection of Intestinal Inflammation by Vascular Adhesion Protein-1-Targeted [68Ga] Ga-DOTA-Siglec-9 Positron Emission Tomography in Murine Models of Inflammatory Bowel Disease | |
| Gabriel et al. | ^ sup 68^ Ga-DOTA-Tyr^ sup 3^-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT | |
| Sergieva | Role of SPECT/CT Imaging with Gamma-emitted Radionuclides in Cancer Patients | |
| Abubakar et al. | Dual Diagnostic Dilemma: Gitelman Syndrome and Incidental Neuroendocrine Tumor in a Young Adult With Refractory Hypokalemia | |
| Maria Koutelou et al. | Spleen visualization in both TTR and AL amyloidosis |